ImmunogenX Email Format
Pharmaceutical ManufacturingCalifornia, United States2-10 Employees
ImmunogenX, Inc. is a clinical-stage pharmaceutical company based in Irvine, California, founded in 2013. It focuses on addressing fundamental needs of individuals with suspected or diagnosed celiac disease and has conducted two Phase 2b trials, including latiglutenase, an investigational medication intended to alleviate common symptoms associated with the condition. The organization operates with a small team and collaborates with researchers and partners to advance a GI-focused pipeline. In recent developments, ImmunogenX became part of an all-stock transaction with First Wave BioPharma, expanding the scope of its late-stage assets and ongoing research efforts in the gastroenterology space. The company’s work situates it within the pharmaceutical manufacturing industry, emphasizing clinical research and development for gastrointestinal disorders.